

## Lactate – Liquizyme

REF: 274 001 (5 x 20 ml) 100 test  
REF: 274 002 200 test

### Intended Use

Spectrum liquizyme Lactate reagent is intended for the in-vitro quantitative, diagnostic determination of lactate in human Plasma and CSF on both automated and manual systems.

### Background

Lactic acid, present in blood entirely as lactate is an intermediary product of carbohydrate metabolism and is derived mainly from muscle cells and erythrocytes. The blood lactate concentration is affected by its production in muscle cells and erythrocytes and its rate of metabolism in the liver. During exercise, blood lactate can increase up to ten times of normal levels. Under normal conditions, the ratio between lactate and pyruvate is constant (10:1). The liver can normally metabolize more lactate than is produced.


In the case of decreased perfusion of the liver, however, removal of lactate by the liver may be significantly reduced. The amount of lactate in cerebrospinal fluid normally parallels blood levels. CSF lactate level is increased in bacterial meningitis, epilepsy, and intracranial hemorrhage. CSF lactate level may be an aid to distinguish between bacterial from viral meningitis.

### Method

Enzymatic colorimetric method (LOX / PAP) with lactate oxidase and 4-aminoantipyrine.

### Assay Principle

Lactate is oxidized to pyruvate and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) by lactate oxidase (LOX). In the presence of peroxidase (POD), hydrogen peroxide reacts with 2,4,6-tribromo-3-hydroxybenzoic acid (THB) and 4-aminoantipyrine (4-AAP) to form a red quinoneimine dye.



The color intensity of the formed red quinoneimine dye is directly proportional to the lactate concentration. It is determined by measuring the increase in absorbance at 546 nm.

### Reagents

**Standard lactate (ST)** 10 mg/dL

#### Reagent 1 (R1 Buffer)

Tris buffer 100 mmol/L  
2,4,6-tribromo-3-hydroxybenzoic acid 2.0 mmol/L  
4-Amino antipyrine 0.8 mmol/L

#### Reagent 2 (R2 Enzyme)

Lactate oxidase >20 U/L  
Peroxidase >15 U/L  
Sodium Azide 0.02 %

For further information, refer to the Lactate reagent material safety data sheet.

### Precautions and Warnings

Do not ingest or inhale. In case of contact with eyes or skin; rinse immediately with plenty of soap and water. In case of severe injuries; seek medical advice immediately.

Reagent (R2) contains sodium azide which may react with copper or lead plumbing.

### SYMBOLS IN PRODUCT LABELLING

	Authorised Representative		Use by/Expiration Date
	For in-vitro diagnostic use		CAUTION. Consult instructions for use
	Batch Code/Lot number		Manufactured by
	Catalogue Number		(Xi) - Irritant
	Consult instructions for use		Temperature Limitation

### Reagent Preparation

#### Prepare working solution as following:

REF:274 001:add 2 ml from R2 to one bottle of R1; mix gently.

Or prepare the working solution according to the number of tests required by mixing 9 volumes of reagent 1 (R1) and 1 volume of reagent 2 (R2), e.g. 900 µl R1 +100 µl R2.

### Reagent Storage and Stability

All reagents are stable until expiration date stated on label when stored refrigerated at 2 – 8 °C. Working solution is stable for 3 months at 2 – 8 °C or 1 week at 15 – 25 °C. Once opened, the reagent and the standard vials are stable for 3 months at the specified temperature if contamination is avoided.

### Deterioration

The working reagent is normally clear or pale pink. Do not use liquizyme lactate reagent if it is turbid or if the absorbance is greater than 0.1 at 546 nm.

### Specimen Collection and Preservation

Plasma and CSF. Do not use serum specimens. Avoid icteric and haemolytic specimens. The only acceptable anticoagulants are fluoride/heparin and iodoacetate/heparin. Collection of satisfactory specimen for lactate analysis requires special procedures to prevent changes of lactate both while and after the specimen is drawn. The patient should be fasting and at complete rest and exercise of the arm or hand should be avoided before or during collection of the specimens. The collected blood should be cooled on ice immediately and separated from the cells within 15 minutes. Once the plasma is separated from the cells, lactate values are stable. Use the CSF samples with addition of glycolysis inhibitor, e.g. sodium fluoride. Lactate in CSF is stable for 3 hours at 20 – 25 °C, for 24 hours at 4 – 8 °C, and for 2 months frozen at -20 °C, stable in plasma for 2 hours at 20 – 25 °C and 2 days at 4 – 8 °C.

### System Parameters

Wavelength	546 nm
Optical path	1 cm
Assay type	End-point
Direction	Increase
Sample : Reagent Ratio	1 : 100
e.g.: Reagent volume	1 ml
Sample volume	10 µl
Temperature	37 °C or 15 – 25 °C
Zero adjustment	Reagent blank
Incubation time	5 minutes at 37 °C or 10 minutes at 15 – 25 °C
Reagent Blank Limits	Low 0.00 AU High 0.25 AU
Sensitivity	0.3 mg/dL (0.033 mmol/L)
Linearity	90 mg/dL (9.99 mmol/L)

### Procedure

	Blank	Standard	Sample
<b>Working Reagent</b>	1.0 ml	1.0 ml	1.0 ml
<b>Standard</b>	-----	10 µl	-----
<b>Sample</b>	-----	-----	10 µl

Mix and incubate for 5 minutes at 37 °C or 10 minutes at 15 – 25 °C. Measure absorbance of specimen (A<sub>specimen</sub>) and standard (A<sub>standard</sub>) against reagent blank within 30 minutes.

## Calculation

$$\text{Lactate conc. (mg/dL)} = \frac{A_{\text{specimen}}}{A_{\text{standard}}} \times 10$$

## Performance Characteristics

### Precision

Within run (Repeatability)

	Level 1	Level 2
n	20	20
Mean (mg/dL)	13.2	52.4
SD	0.32	0.84
CV%	2.42	1.60

Run to run (Reproducibility)

	Level 1	Level 2
n	20	20
Mean (mg/dL)	14.0	54.7
SD	0.29	0.75
CV%	2.07	1.37

## Quality Control

Normal and abnormal commercial control serum of known concentrations should be analyzed with each run.

## Methods Comparison

A comparison between Spectrum Lactate reagent and a commercial reagent of the same methodology was performed on 200 human sera. A correlation of 0.992 was obtained.

## Sensitivity

When run as recommended, the minimum detection limit of the assay is 0.3 mg/dL (0.033 mmol/L).

## Linearity

The reaction is linear up to lactate concentration of 90 mg/dL (9.99 mmol/L), specimens showing higher concentration should be diluted 1+1 using physiological saline, reassayed and the result multiplied by two.

## Interfering substance

### Haemolysis

Haemoglobin levels higher than 2.5 g/L (0.16 mmol/L) increase the apparent lactate concentration significantly.

### Icterus

Bilirubin levels higher than 4.0 mg/dL (68 mmol/L) decrease apparent lactate concentration significantly.

### Lipemia

No significant interference.

### Ascorbic acid

Physiological ascorbic acid concentrations do not interfere with the test. Ascorbic Acid levels higher than 5 mg/dL (284 mmol/l) decrease the apparent lactate concentration significantly.

## Expected Values

Plasma	Venous	4.5 – 19.8 mg/dL	0.5 – 2.2 mmol/L
	Arterial	4.5 – 14.4 mg/dL	0.5 – 1.6 mmol/L
CSF	Adult	10 – 22 mg/dL	1.1 – 2.4 mmol/L
	Neonates	10 – 60 mg/dL	1.1 – 6.7 mmol/L

**Spectrum Diagnostics does not interpret the results of a clinical laboratory procedure; interpretation of the results is considered the responsibility of qualified medical personnel. All indications of clinical significance are supported by literature references.**

## Analytical Range

0.3 – 90 mg/dL ( 0.033 – 9.99 mmol/L).

## Waste Disposal

This product is made to be used in professional laboratories.

Please consult local regulations for a correct waste disposal.

**S56:** dispose of this material and its container at hazardous or special waste collection point.

**S57:** use appropriate container to avoid environmental contamination.

**S61:** avoid release in environment. refer to special instructions/safety data sheets.

## Reference

1. Bailey EM, Domenico P, Cunha BA. Bacterial or viral meningitis? Measuring lactate in CSF can help you know quickly. *Meningitis*. 1990;88:217-223.
2. Field M, Block JB, Levin R, Rall DP. Significance of blood lactate elevations among patients with acute leukemia and other neoplastic proliferative disorders. *Am J Med*. 1996;40:528-547.
3. Klein TO. Nervensysteme. In: Greiling H, Gressner AM, eds. *Lehrbuch der Klinischen Chemie und Pathobiochemie*. Stuttgart:Schattauer; 1987:859-893.
4. Sacks DB. Carbohydrates. In: Burtis CA, Ashwood ER, eds. *Tietz Fundamentals of Clinical Chemistry*. 4th ed. Philadelphia:WB Saunders; 1996:351-374.
5. Sacks DB. Carbohydrates in: Burtis CA, Ashwood ER, eds. *Tietz Textbook of Clinical Chemistry*. 2nd ed. Philadelphia:WB Sander; 1994:928-1001.
6. Tietz NW, ed. *Clinical Guide to laboratory tests*. 3rd ed. Philadelphia: WB Saunders; 1995:351-374.

## ORDERING INFORMATION

CATALOG NO.	QUANTITY
274 001	100 test
274 002	200 test



**Egyptian Co for Biotechnology - Spectrum Diagnostics (S.A.E)**

Obour city industrial area. block 20008 piece 19 A. Cairo. Egypt.

Tel: +202 4489 2248 - Fax: +202 4489 2247

www.spectrum-diagnostics.com

E-mail: info@spectrum-diagnostics.com



**MDSS GmbH**  
Schiffgraben 41  
30175 Hannover, Germany

